Goel Kapil, Verma Madhur, Sharma Nikita, Parida Swayam Pragyan, Bhardwaj Anu, Nadda Anuradha, Sharma Sahil, Sen Arunima, John Jacob, Bansal Adarsh, Gupta Madhu
Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Community and Family Medicine, All India Institute of Medical Sciences, Bathinda, Punjab, India.
Indian J Community Med. 2024 Dec;49(Suppl 2):S139-S145. doi: 10.4103/ijcm.ijcm_740_24. Epub 2024 Dec 30.
Typhoid is a major public health concern in India, particularly among those dwelling in urban slums with poor sanitation. The disease caused by spread majorly through contaminated food and water. The economic burden of the disease is catastrophic and affects both families and the government making a strong case for including typhoid vaccines in the national immunization schedule. The World Health Organization has prequalified several vaccines and has recommended their use in endemic areas. While there is robust evidence for vaccination of children from India and other LMICs, the case for adult vaccination remains less clear. The Indian Association of Preventive and Social Medicine acknowledges the necessity to adopt a widespread typhoid immunization program, along with other preventive strategies, especially in the vulnerable pockets. IAPSM recommends focusing on newer-generation Typhoid Conjugate Vaccines (TCVs), which provide long-lasting and superior immunological benefits, and are effective across all ages including adults. IAPSM suggests routine use of Typbar-TCV™ for adults up to 45 years old in India. The organization also highlights the necessity for post-marketing surveillance of these vaccines, to monitor the long-term safety and effectiveness of various vaccines in different communities. IAPSM encourages members to take front-line efforts in their community health service areas, and finally appeals for the development of vaccines to cover a more extensive range of Salmonella infections so that control over typhoid can be strengthened.
伤寒是印度主要的公共卫生问题,尤其是在卫生条件差的城市贫民窟居民中。这种疾病主要通过受污染的食物和水传播。该疾病的经济负担是灾难性的,对家庭和政府都会产生影响,这有力地说明了应将伤寒疫苗纳入国家免疫规划。世界卫生组织已对几种疫苗进行了预认证,并建议在流行地区使用。虽然有充分证据支持为印度和其他低收入和中等收入国家的儿童接种疫苗,但成人接种疫苗的情况仍不太明确。印度预防与社会医学协会承认有必要实施广泛的伤寒免疫计划以及其他预防策略,特别是在弱势群体集中的地区。该协会建议重点关注新一代伤寒结合疫苗(TCV),这种疫苗能提供持久且卓越的免疫效果,对包括成人在内的所有年龄段都有效。该协会建议在印度对45岁及以下的成年人常规使用Typbar-TCV™。该组织还强调了对这些疫苗进行上市后监测的必要性,以监测各种疫苗在不同社区的长期安全性和有效性。该协会鼓励其成员在社区卫生服务领域发挥一线作用,最后呼吁研发能覆盖更广泛沙门氏菌感染范围的疫苗,以便加强对伤寒的控制。